BioSpace News Archive

Ikena Oncology, Inc. announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023.

Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, announced that CureDuchenne Ventures, the strategic investment arm of CureDuchenne, has made an equity investment in Locanabio.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2023.

Cyclerion Therapeutics, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023.

Investigators from Baylor College of Medicine in collaboration with Immunai have published results from a clinical study in which Immunai’s technology helped identify BTG1 as a novel molecular target that can be used to enhance the potency of natural killer T - and T cell-based cancer immunotherapy.

Regulatory News: POXEL SA announced TWYMEEG® Fiscal Year and fourth quarter 2022 results, as recently published by Sumitomo Pharma, its partner commercializing TWYMEEG in Japan.

For more than a decade, Bionix has supplied the radiation oncology sector of the healthcare industry with Accu-Tatt®, an all-inclusive, sterile, single-use tattooing device that marks targeted areas on a patient’s body for proper alignment during radiation therapy procedures.